Drug Profile
Dersimelagon - Mitsubishi Tanabe Pharma
Alternative Names: [14C] MT-7117; Dersimelagon; MT-7117; MT-7117-MBLatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Carboxylic acids; Cyclopentanes; Fluorinated hydrocarbons; Phenyl ethers; Piperidines; Pyrrolidines; Skin disorder therapies; Small molecules
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Erythropoietic protoporphyria
- Phase II Diffuse scleroderma
- No development reported Autoimmune disorders
Most Recent Events
- 14 Feb 2024 Mitsubishi Tanabe Pharma America completes a phase II trial in Diffuse scleroderma (In the elderly, In adults) in USA, Belgium, Canada, Germany, Italy, Spain, Poland and the United Kingdom (PO) (NCT04440592) (EudraCT2020-000134-17)
- 11 Dec 2023 Phase-III clinical trials in Erythropoietic protoporphyria (In adolescents, In adults, In the elderly) in USA (PO) (NCT06144840)
- 22 Nov 2023 Mitsubishi Tanabe Pharma plans the phase III INSPIRE trial for Erythropoietic protoporphyria (In adolescents, In adults, In the elderly) in USA, Australia, Bulgaria, Czechia, France, Italy, the Netherlands, Poland, Spain and the UK (NCT06144840)